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INTRODUCTION
Adenoid cystic carcinoma (ACC) is a malignancy of secretory 
glands, including the lacrimal and salivary gland, which are 
highly aggressive and prone to local recurrence, and spread to 
adjacent tissues.1 ACC is characterized by a slow but persistent 
progression, with multiple local recurrence, and metastasis to 
the lung, bone, and brain, occurring in approximately 50% of 
patients.2,3 There are only a few studies of lacrimal gland ACC, 
in comparison with salivary gland ACC, due to rarity of the tu-
mor. Advanced stage, solid architecture, high histologic grade, 
perineural invasion, and positive surgical resection margin are 
known as factors related to poor prognosis of salivary gland 
ACC.4-6 Lacrimal gland ACC showed clinical features of younger 
age and worse prognosis compared to salivary gland ACC.7 The 
causes of worse prognosis of lacrimal gland ACC were the high 
rate of incomplete excision rate due to complex orbital anato-
my, invasion to nearby structures, and subsequent metasta-
ses.1,8
Primary treatments of lacrimal gland ACC are en bloc surgi-
cal excision and postoperative radiation, as needed.9 Recently, 
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neoadjuvant intra-arterial cytoreductive chemotherapy has 
been introduced to improve overall survival (OS) and decrease 
recurrence in 19 lacrimal gland ACCs, although controversy ex-
ists.10,11 Neutron radiation therapy achieved 80% of 5 year local 
control in 11 cases, although late recurrence and distant metas-
tasis remained as challenges.12 No effective treatment is avail-
able in cases of recurrence or metastasis of lacrimal gland ACC. 
New treatments targeting this rare and life-threatening cancer 
are needed.
Recent advances have highlighted that alterations in both 
reactive oxygen species (ROS) and autophagy regulation are 
associated with cancer initiation and progression. It is now 
clear that these processes are mutually linked and play a cru-
cial role in cancer progression and in response to cancer ther-
apeutics.13-16 Autophagy, a self-digestion process that facilitates 
cellular survival by maintaining energy homeostasis and macro-
molecular synthesis during cellular stress and nutrient depriva-
tion, which can also induce ROS generation.13,15-20 Recently, it 
was demonstrated that ROS can induce autophagy through sev-
eral distinct mechanisms involving Atg4, catalase, and the mito-
chondrial electron transport chain, and some of the ROS stimu-
lator, such as 2-methoxyestrodial and arsenic trioxide which are 
under clinical investigation as cancer treatments.19,21 Autophagy 
can lead to cell-survival as well as cell-death responses and 
could be selective toward cancer cells. Cancer cell is able to sur-
vive in such an environment of hypoxia and nutrient depriva-
tion, through angiogenesis and/or aerobic glycolysis. In highly 
aggressive malignant tumor requiring high metabolic demand, 
alternative metabolic pathway such as autophagy can provide 
cellular energy by recycle of cytoplasmic component, acting as a 
cytoprotective mechanism that help cancer cells resist anti-can-
cer treatments.7,22 In the case of salivary gland ACC, ongoing in-
vestigations are taking place to better understand autophagy re-
lated proteins such as beclin-1 and YM155 and to develop 
chemotherapeutic agents targeting these markers.23-26 However, 
no study has yet been conducted to investigate autophagy and 
ROS status in lacrimal gland ACC. The aim of this study was to 
investigate the expression and its implications of autophagy 
and ROS-related proteins in lacrimal gland ACC, compared to 
salivary gland ACC.
MATERIALS AND METHODS
Patient selection and clinicopathologic evaluation
Formalin-fixed, paraffin-embedded tissue samples of lacrimal 
gland ACC, collected from January 1997 to December 2012, at 
Severance Hospital, Yonsei University College of Medicine, were 
used for analyses. The study was approved by the Institutional 
Review Board of Severance Hospital. Clinical informations such 
as age at surgery, gender, tumor side, symptoms, and visual 
acuity were obtained from medical chart recordings. Tumor 
stage classifications followed the 7th American Joint Commit-
tee on Cancer staging system, and histologic features of hema-
toxylin and eosin slides were reviewed by a specialized patholo-
gist (JSK). Histologic grading of tumors followed the indications 
established by Szanto, et al.27 as follows: grade I, no solid com-
ponent; grade II, ACC with less than 30% solid component; and 
grade III, ACC with more than 30% solid component. Histologic 
type was determined by predominant morphological growth 
patterns and divided into cribriform, tubular, and solid patterns. 
Perineural invasion, tumor margin (expanding, infiltrative), 
and tumor involvement in the surgical resection margin were 
evaluated. As a control group, 64 cases of salivary gland ACC in 
the same time periods of tissue collection were included.
Immunohistochemistry
The antibodies used for immunohistochemistry (IHC) in this 
study are listed in Supplementary Table 1 (only online). IHC 
was performed on formalin-fixed, paraffin-embedded tissue 
sections. After sectioning the tissue at a thickness of 3 μm, the 
samples were deparaffinized and rehydrated using xylene and 
alcohol solutions. IHC was performed using the Ventana Dis-
covery XT automated staining system (Ventana Medical Sys-
tem, Tucson, AZ, USA). CC1 buffer (Cell Conditioning 1; citrate 
buffer, pH 6.0; Ventana Medical System) was used to wash 
samples for antigen exposure. IHC included the appropriate 
positive and negative controls.
IHC was performed to measure expression of proteins related 
to autophagy including beclin-1, light chain (LC) 3A, LC3B, p62 
and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 
(BNIP3), and ROS including catalase, thioredoxinreductase, 
glutathione S-transferasepi (GSTpi), thioredoxin interacting 
protein, and manganese superoxide dismutase (MnSOD) in 11 
cases of lacrimal gland ACC and 64 cases of salivary gland ACC.
Interpretation of immunohistochemical results
Results of IHC were defined as the proportion of stained cells× 
immunostaining intensity. The proportion of stained cell was 
defined as follows: 0 as negative, 1 as less than 30% positivity, 
and 2 as 30% or more positivity. Immunostaining intensity was 
defined as follows: 0 as negative, 1 as weak, 2 as moderate, and 
3 as strong. The proportion of stained cells×immunostaining in-
tensity was defined as follows: 0–1 was negative, 2–6 was posi-
tive.28
Statistical analysis 
Data were statistically processed using SPSS for Windows ver-
sion 12.0 (SPSS Inc., Chicago, IL, USA). The Student’s t-test and 
Fisher’s exact test were used for continuous and categorical 
variables, respectively. Statistical significance was defined as 
p<0.05. Kaplan-Meier survival curves and log-rank statistics 
were employed to evaluate survival time and time to tumor me-
tastasis, respectively. Multivariate regression analysis was per-
formed using the Cox proportional hazards model.
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Table 2. Comparison to the Expression of Autophagy and Redox-Related 
Proteins between Lacrimal Gland ACC and Salivary Gland ACC
Parameters
Total,
n=75 (%)
Lacrimal gland 
ACC,
n=11 (%)
Salivary gland 
ACC,
n=64 (%)
p value
Beclin-1 (T) 0.742
Negative 50 (66.7) 8 (72.7) 42 (65.6)
Positive 25 (33.3) 3 (27.3) 22 (34.4)
LC3A (T) 0.333
Negative 67 (89.3) 9 (81.8) 58 (90.6)
Positive 8 (10.7) 2 (18.2) 6 (9.4)
LC3A (S) 0.719
Negative 56 (74.7) 9 (81.8) 47 (73.4)
Positive 19 (25.3) 2 (18.2) 17 (26.6)
LC3B (T) 0.269
Negative 55 (73.3) 10 (90.9) 45 (70.3)
Positive 20 (26.7) 1 (9.1) 19 (29.7)
p62 (T) 0.272
Negative 68 (90.7) 9 (81.8) 59 (92.2)
Positive 7 (9.3) 2 (18.2) 5 (7.8)
BNIP3 (T) 0.477
Negative 71 (94.7) 10 (90.9) 61 (95.3)
Positive 4 (5.3) 1 (9.1) 3 (4.7)
Catalase (T) 0.742
Negative 50 (66.7) 8 (72.7) 42 (65.6)
Positive 25 (33.3) 3 (27.3) 22 (34.4)
Catalase (S) 1.000
Negative 70 (93.3) 11 (100.0) 59 (92.2)
Positive 5 (6.7) 0 (0.0) 5 (7.8)
TxNR 0.341
Negative 65 (86.7) 11 (100.0) 54 (84.4)
Positive 10 (13.3) 0 (0.0) 10 (15.6)
GSTpi (T) 1.000
Negative 16 (21.3) 2 (18.2) 14 (21.9)
Positive 59 (78.7) 9 (81.8) 50 (78.1)
GSTpi (S) 0.006*
Negative 60 (80.0) 5 (45.5) 55 (85.9)
Positive 15 (20.0) 6 (54.5) 9 (14.1)
TxNIP 1.000
Negative 72 (96.0) 11 (100.0) 61 (95.3)
Positive 3 (4.0) 0 (0.0) 3 (4.7)
MnSOD (T) 0.046*
Negative 12 (16.0) 4 (36.4) 8 (12.5)
Positive 63 (84.0) 7 (63.6) 56 (87.5)
MnSOD (S) 0.681
Negative 63 (84.0) 10 (90.9) 53 (82.8)
Positive 12 (16.0) 1 (9.1) 11 (17.2)
S, stromal; T, tumor; BNIP3, BCL2/adenovirus E1B 19 kDa protein-interacting 
protein 3; TxNR, thioredoxinreductase; GSTpi, glutathione S-transferasepi; 
TxNIP, thioredoxin interacting protein; MnSOD, manganese superoxide dis-
mutase.
Data are presented as the number of cases with positive expression (%).
*Characters refer to statistical significance (p<0.05).
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Fig. 1. Immunohistochemical expression of GSTpi and MnSOD in lacrimal and salivary gland adenoid cystic carcinoma (ACC). Expression of GST in stro-
mal component was higher and MnSOD in cell component was lower in lacrimal gland ACC than in salivary gland ACC (×100). GSTpi, glutathione S-
transferasepi; MnSOD, manganese superoxide dismutase; H&E, hematoxylin and eosin.
Lacrimal ACC
H&E
GSTpi
MnSOD
Salivary ACC
Cu
m
ul
at
ive
 d
ise
as
e-
fre
e 
su
rv
iva
l
Cu
m
ul
at
ive
 d
ise
as
e-
fre
e 
su
rv
iva
l
Cu
m
ul
at
ive
 d
ise
as
e-
fre
e 
su
rv
iva
l
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
Months Months Months
0 20 40 60 80 0 20 40 60 80 0 50 100 150 200 250
LC3B negative BNIP3 negative
LC3A (S) negative
LC3B positive BNIP3 positive LC3A (S) positive
p=0.002 p=0.002
p=0.005
Fig. 2. Kaplan-Meier curves for disease-free survival and overall survival of lacrimal gland ACC, correlated with expression of the autophagy related pro-
teins such as LC3A, LC3B, and BNIP3. BNIP3, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; ACC, adenoid cystic carcinoma; LC, light chain.
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RESULTS
Basal characteristics of lacrimal gland ACC
This study included 11 cases of lacrimal gland ACC (Table 1). 
Clinical characteristics were 21–72 years of age, and 3 were fe-
male and 8 were male. The size of the tumor was 2.5 to 4.0 cm, 
and the main histologic type was cribriform type (n=5). The 
most common histologic grade was grade 1 (n=5). Lymphovas-
cular invasion was observed in 2 cases, local recurrence in 5 
cases, and distant metastases in 7 cases [brain (n=5) and lung 
(n=2)]. Three patients died of disease.
Expression of autophagy and ROS-related proteins  
in lacrimal gland ACC: comparison with salivary 
gland ACC
Autophagy and ROS-related proteins expression was compared 
between lacrimal gland ACC and salivary gland ACC (Table 2). 
Compared to salivary gland ACC, lacrimal gland ACC showed 
higher expression of GSTpi in stromal component (p=0.006), 
and lower expression of MnSOD in epithelial component 
(p=0.046) (Fig. 1).
Impact of expression of autophagy and ROS-related 
proteins on patient prognosis in lacrimal gland ACC
In lacrimal gland ACC, the effect of expression of autophagy 
and ROS-related proteins on the prognosis was evaluated using 
univariate analysis (Fig. 2, Table 3). Factors associated with a 
shorter disease-free survival (DFS) were LC3B and BNIP3 posi-
tivity in epithelial component (both p=0.002). The factor associ-
ated with shorter OS was LC3A positivity in stromal component 
(p=0.005), however, no independent influencing factors on 
prognosis were found by multivariate Cox analyses (Table 4).
DISCUSSION
In this study, expression of autophagy and ROS-related proteins 
was examined in lacrimal gland ACC, in comparison to salivary 
gland ACC, and effects of prognostic variables effects on DFS 
and OS in lacrimal gland ACC were explored using the log-rank 
test. First, GSTpi isoenzyme protein expression level was higher 
in lacrimal gland ACC than salivary gland ACC. Until now, 
there has been no study on the expression of GSTpi in ACC. 
GSTpi isoenzyme is known to suppress toxin-induced DNA 
damage by catalyzing the conjugation of electrophilic mole-
cules with glutathione.29,30 High GSTpi expression is consistently 
found in tumor cells, and seems to be directly related to the de-
velopment of chemotherapeutic resistance in several types of 
cancer, especially in breast cancer by detoxifying chemothera-
peutic drugs inside neoplastic cells.11,12,31,32 GSTpi expression in 
stromal cells in breast tumor microenvironment, namely can-
cer-associated fibroblast, is also recognized to have major roles 
in cancer progression.32 Likewise, higher level of GSTpi in stro-
Table 3. Univariate Analysis by Log-Rank Test of the Impact of Autoph-
agy and Redox-Related Proteins Expression in Lacrimal Gland ACC on 
Disease-Free Survival and Overall Survival Times
Parameters
Disease-free survival Overall-survival
95% CI p value 95% CI p value
Beclin-1 (T) 0.201 N/A
Negative 44 (30–58) N/A
Positive 24 (0–50) N/A
LC3A (T) 0.761 0.431
Negative 44 (30–59) 74 (61–86)
Positive 27 (0–77) 245 (245–245)
LC3A (S) 0.634 0.005*
Negative 40 (24–55) 201 (97–305)
Positive 35 (35–35) 38 (38–38)
LC3B (T) 0.002* N/A
Negative 44 (31–56) N/A
Positive 1 (1–1) N/A
p62 (T) 0.100 N/A
Negative 45 (31–58) N/A
Positive 18 (0–52) N/A
BNIP3 (T) 0.002* N/A
Negative 44 (31–56) N/A
Positive 1 (1–1) N/A
Catalase (T) 0.101 0.061
Negative 44 (31–58) 201 (97–305)
Positive 23 (0–49) 53 (32–73)
Catalase (S) N/A N/A
Negative N/A N/A
Positive N/A N/A
TxNR N/A N/A
Negative N/A N/A
Positive N/A N/A
GSTpi (T) 0.534 N/A
Negative 43 (33–52) N/A
Positive 37 (23–52) N/A
GSTpi (S) 0.714 N/A
Negative 39 (32–46) N/A
Positive 37 (17–56) N/A
TxNIP N/A N/A
Negative N/A N/A
Positive N/A N/A
MnSOD (T) 0.397 0.808
Negative 51 (24–78) 75 (70–80)
Positive 34 (22–46) 210 (123–297)
MnSOD (S) N/A N/A
Negative N/A N/A
Positive N/A N/A
ACC, adenoid cystic carcinoma; CI, confidence interval; LC, light chain; T, tu-
mor; S, stromal; BNIP3, BCL2/adenovirus E1B 19 kDa protein-interacting pro-
tein 3; TxNR, thioredoxinreductase; GSTpi, glutathione S-transferasepi; 
TxNIP, thioredoxin interacting protein; MnSOD, manganese superoxide dis-
mutase.
*Characters refer to statistical significance (p<0.05).
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mal cells of lacrimal gland ACC could be related to chemoresis-
tance, although the mechanism is unclear and requires a fur-
ther investigation.
The major antioxidant enzyme that scavenges superoxide 
anion radical in mitochondria is MnSOD.33 In our study, the ex-
pression level of MnSOD was lower in lacrimal gland ACC than 
salivary gland ACC. MnSOD was reported to be expressed low-
er in tumor tissue than in normal tissue, playing a role as a tu-
mor suppressor.10 MnSOD have been demonstrated to play a 
critical role in the development and progression of cancer.33 
Many human cancer cells such as neuroblastoma, lung cancer, 
hepatoma, esophageal cancer, and colorectal cancer harbor 
low levels of MnSOD proteins and enzymatic activity.34-38 Enzy-
matic activity of MnSOD rapidly declined in stage IV colon can-
cer tissue, suggesting that a decrease of in MnSOD in cancer 
tissue could be related to aggressiveness of tumor.39 However, 
some cancer cells possess high levels of MnSOD proteins and 
enzymatic activity,40 suggesting that differential regulation of 
MnSOD exists in cancer cells, depending on the type and stage 
of cancer development. Lower expression of MnSOD proteins 
in lacrimal gland ACC could be associated with poorer progno-
sis of lacrimal gland ACC than salivary gland ACC.
Cancer is one of the first diseases found to genetically be 
linked to autophagy malfunction.18,41 A study has reported that 
beclin-1, an autophagy related protein, was correlated with OS 
in salivary gland ACC.42 In this study, there was no statistical 
difference in beclin-1 expression level between lacrimal gland 
and salivary gland. Also, LC3B and BNIP3 were closely associ-
ated with shorter DFS in lacrimal gland. Expression of LC3B in 
breast cancer and BNIP3 in lung cancer, larynx cancer, and 
breast cancer were related to poor prognosis, compatible to our 
results.43-46 In addition, LC3A expression in stromal component 
was associated with shorter OS in our study, which was also 
compatible to the previous reports that the expression of LC3A 
was a poor prognostic factor in other cancers including stom-
ach cancer, ovary cancer, and lung cancer.47-49 Current cancer 
therapies, including chemotherapy and radiation, are known to 
induce autophagy within tumor cells.50 Recently, autophagy re-
lated to ROS, pathway is thoroughly discussed as a target of anti-
cancer treatment.19,21 ROS produced endogenously, by deranged 
metabolism of cancer cells, or exogenously, by ROS-generating 
drugs, have been shown to promote macroautophagy, a lyso-
somal pathway of self-degradation with essential prosurvival 
functions.16 Furthermore, there are safe, clinically available 
drugs known to both inhibit and stimulate autophagy, however, 
there are conflicting positive and negative effects of autophagy 
reported and no current consensus on how to manipulate au-
tophagyto improve clinical outcomes.
In conclusion, lacrimal ACC showed different expression of 
ROS related protein from salivary gland ACC. Lacrimal gland 
ACC was shown to express higher level of GSTpi in stromal 
component and lower level of MnSOD in epithelial component 
than salivary gland ACC. Also, autophagy related proteins such 
as LC3A, LC3B, and BNIP3 were associated with poor progno-
sis in lacrimal gland ACC. We found that some of autophagy 
and ROS related proteins were expressed in both cell and stro-
mal component of lacrimal gland ACC. Further studies are 
mandatory to understand the role of autophagy in the patho-
genesis, and to confirm association between autophagy and 
ROS pathways, in order to find out whether inhibition or stimu-
lation of autophagy and/or ROS is beneficial in the treatment of 
lacrimal gland ACC. Our data would provide a basis for further 
study of investigation of autophagy and ROS pathway as targets 
for possible anticancer treatment.
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